Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3154528rdf:typepubmed:Citationlld:pubmed
pubmed-article:3154528lifeskim:mentionsumls-concept:C0027912lld:lifeskim
pubmed-article:3154528lifeskim:mentionsumls-concept:C0277785lld:lifeskim
pubmed-article:3154528lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:3154528lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:3154528lifeskim:mentionsumls-concept:C0221765lld:lifeskim
pubmed-article:3154528lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:3154528lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:3154528lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:3154528pubmed:issue6lld:pubmed
pubmed-article:3154528pubmed:dateCreated1991-4-5lld:pubmed
pubmed-article:3154528pubmed:abstractTextNeuroendocrine and mood responses to a 60 mg oral dose of the serotonin-releasing agent, fenfluramine, were assessed in ten neuroleptic-free, chronic schizophrenic patients and in age- and sex-matched normal control subjects. The prolactin (PRL) response to fenfluramine was significantly blunted in the schizophrenic subjects. Growth hormone and cortisol levels were not differentially affected by the challenge. There was no significant effect of fenfluramine on mood in either group. The blunted PRL response in the schizophrenic group suggests serotonergic dysfunction; possible mechanisms of this finding and implications for treatment are considered.lld:pubmed
pubmed-article:3154528pubmed:languageenglld:pubmed
pubmed-article:3154528pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3154528pubmed:citationSubsetIMlld:pubmed
pubmed-article:3154528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3154528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3154528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3154528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3154528pubmed:statusMEDLINElld:pubmed
pubmed-article:3154528pubmed:issn0920-9964lld:pubmed
pubmed-article:3154528pubmed:authorpubmed-author:EbsteinBBlld:pubmed
pubmed-article:3154528pubmed:authorpubmed-author:LererBBlld:pubmed
pubmed-article:3154528pubmed:authorpubmed-author:SilverHHlld:pubmed
pubmed-article:3154528pubmed:authorpubmed-author:WellerM PMPlld:pubmed
pubmed-article:3154528pubmed:authorpubmed-author:RakBBlld:pubmed
pubmed-article:3154528pubmed:authorpubmed-author:CaletCClld:pubmed
pubmed-article:3154528pubmed:authorpubmed-author:BlackerMMlld:pubmed
pubmed-article:3154528pubmed:authorpubmed-author:DrummerDDlld:pubmed
pubmed-article:3154528pubmed:issnTypePrintlld:pubmed
pubmed-article:3154528pubmed:volume1lld:pubmed
pubmed-article:3154528pubmed:ownerNLMlld:pubmed
pubmed-article:3154528pubmed:authorsCompleteYlld:pubmed
pubmed-article:3154528pubmed:pagination405-10lld:pubmed
pubmed-article:3154528pubmed:dateRevised2010-9-2lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:meshHeadingpubmed-meshheading:3154528-...lld:pubmed
pubmed-article:3154528pubmed:articleTitleNeuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction.lld:pubmed
pubmed-article:3154528pubmed:affiliationJerusalem Mental Health Center-Ezrath Nashim Hospital, Israel.lld:pubmed
pubmed-article:3154528pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3154528pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed